Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Regulatory
150 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Nov 14, 2019 | openfda |
Data updated 22 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Venetoclax | 31 | 0 | 31 |
| Imatinib | 27 | 26 | 1 |
| Doxorubicin | 26 | 1 | 25 |
| Dasatinib | 25 | 23 | 2 |
| Melphalan | 24 | 0 | 24 |
| Mercaptopurine | 23 | 2 | 21 |
| Thioguanine | 21 | 0 | 21 |
| Cytarabine | 10 | 3 | 7 |
| Methotrexate | 10 | 2 | 8 |
| Tazemetostat | 10 | 10 | 0 |
| Vemurafenib | 10 | 9 | 1 |
| Daunorubicin | 9 | 1 | 8 |
| Ibrutinib |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 9 |
| 3 |
| 6 |
| Asparaginase | 8 | 0 | 8 |
| Chemotherapy | 7 | 7 | 0 |
| Larotrectinib | 4 | 4 | 0 |
| Midostaurin | 4 | 3 | 1 |
| Ponatinib | 4 | 4 | 0 |
| R3Mab | 4 | 4 | 0 |
| Ruxolitinib | 4 | 4 | 0 |
| GSK126 | 3 | 3 | 0 |
| Nilotinib | 3 | 3 | 0 |
| Crizotinib | 2 | 2 | 0 |
| Letetresgene Autoleucel | 2 | 2 | 0 |
| Lometrexol | 2 | 2 | 0 |
| Palbociclib | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Salinomycin | 2 | 2 | 0 |
| Vincristine | 2 | 1 | 1 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK Inhibitor TAE684 | 1 | 1 | 0 |
| Asciminib | 1 | 1 | 0 |
| Atezolizumab | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| Bosutinib | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cisplatin | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| EPZ011989 | 1 | 1 | 0 |
| Erdafitinib | 1 | 1 | 0 |
| Etoposide | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| Gemcitabine | 1 | 0 | 1 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Imatinib Mesylate | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JQ-1 | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| JQEZ5 | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MTOR Inhibitor | 1 | 1 | 0 |
| NCT00137111 | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| Olaparib | 1 | 1 | 0 |
| Panobinostat | 1 | 1 | 0 |
| Pomalidomide | 1 | 0 | 1 |
| Sirolimus | 1 | 1 | 0 |
| Sunitinib | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tyrosine Kinase Inhibitor | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.